Trypanosoma cruzi calreticulin: immune evasion, infectivity, and tumorigenesis
Author
dc.contributor.author
Ramírez Toloza, Galia
Author
dc.contributor.author
Sosoniuk Roche, Eduardo
Author
dc.contributor.author
Valck Calderón, Carolina
Author
dc.contributor.author
Aguilar Guzmán, Lorena
Author
dc.contributor.author
Ferreira, Viviana
Author
dc.contributor.author
Ferreira Vigouroux, Luis
Admission date
dc.date.accessioned
2020-05-13T13:26:14Z
Available date
dc.date.available
2020-05-13T13:26:14Z
Publication date
dc.date.issued
2020
Cita de ítem
dc.identifier.citation
Trends in Parasitology 36(4):368-381
es_ES
Identifier
dc.identifier.other
10.1016/j.pt.2020.01.007
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/174686
Abstract
dc.description.abstract
To successfully infect, Trypanosome cruzi evades and modulates the host immune response. T. cruzi calreticulin (TcCalr) is a multifunctional, endoplasmic reticulum (ER)-resident chaperone that, translocated to the external microenvironment, mediates crucial host-parasite interactions. TcCalr binds and inactivates C1 and mannose-binding lectin (MBL)/ficolins, important pattern- recognition receptors (PRRs) of the complement system. Using an apoptotic mimicry strategy, the C1-TcCalr association facilitates the infection of target cells. T. cruzi infection also seems to confer protection against tumorigenesis. Thus, recombinant TcCalr has important antiangiogenic properties, detected in vitro, ex vivo, and in ovum, most likely contributing at least in part, to its antitumor properties. Consequently, TcCalr is useful for investigating key issues of host-parasite interactions and possible new immunological/pharmacological interventions in the areas of Chagas' disease and experimental cancer.